The hidradenitis suppurativa (HS) market is geographically diverse, with North America leading current adoption and Asia-Pacific (APAC) rapidly emerging as a growth hotspot. Regional differences in healthcare infrastructure, awareness, and patient demographics influence market dynamics, making regional analysis critical for stakeholders.

North America dominates, accounting for 40% of global revenue in 2023 (Market Research Future). This leadership stems from early adoption of advanced therapies, robust clinical trial networks, and high HS prevalence (2.5% of population). The U.S. and Canada are home to major players like Pfizer and AbbVie, which invest $200 million annually in HS R&D. To understand regional drivers, the HS Market Regional Growth section of the report details adoption rates, key players, and regulatory impacts in each region.

APAC is surging, with a projected 9.5% CAGR (2024-2030). China and India, driven by urbanization and rising obesity rates, lead this growth. China’s 2026 “National HS Awareness Campaign” boosted diagnosis by 30%, increasing demand for treatments. India’s HS market, meanwhile, saw a 45% rise in biologic sales since 2022, fueled by local production and insurance coverage. These regions now account for 25% of global HS revenue, up from 15% in 2020.

Europe follows closely, with the EU’s centralized healthcare system enabling consistent access to therapies. However, Eastern Europe lags, with only 50% of HS patients receiving biologics (2026 European Dermatology Forum). As APAC invests in dermatology infrastructure, the HS market is expected to shift toward this region, with APAC projected to capture 30% of revenue by 2030. Regional dynamics thus remain pivotal in shaping the HS market’s future.